Transforming to deliver Business update Financial performance Outlook Appendices sanofi Transforming to deliver Business update Financial performance Outlook Appendices sonofi O Q4 and Full Year 2021 Results Play to Win February 4th, 2022 Transforming to deliver Business update Financial performance Outlook Appendices Forward-looking statements This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forwardlooking statements are state ...

Sanofi (NASDAQ:SNY) Q4 2021 Results Conference Call February 4, 2022 7:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - Global Business Unit Head Thomas Triomphe - Global Business Unit Head Olivier Charmeil - Global Business Unit Head Julie Van Ongevalle - Global Business Unit Head Jean-Baptiste de Chatillon - CFO John Reed - EVP, Global Head of Research & Development Conference Call Participants Wimal Kapadia - Bernstein Richard Vosser - JP Morgan Luisa Hector - ...

Exhibit 99.1 Sanofi announces positive Phase 1/2 study interim results for its first mRNA- based vaccine candidate PARIS – September 28, 2021 – Positive interim results from a Phase 1/2 study1 of Sanofi's mRNA-based COVID-19 vaccine candidate confirm the potential of recently-acquired Translate Bio's messenger RNA (mRNA) and lipid nanoparticle (LNP) platform and support Sanofi's mRNA strategy. The initial data from Phase 1/2 showed neutralizing antibody seroconversion (defined as 4-fold increase vs baseline ...

Exhibit 99.5 Press Release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY) Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ³50% PD-L1 expression PARIS and TARRYTOWN, NY – June 25, 2021 - The European Commission (EC) has approved Sanofi and Regeneron's PD-1 inhibitor Libtayo® (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have ³50% PD-L1 expression and no EG ...

FORM 20-F 2020 SANOFI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 20-F Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

FORM 20-F 2019 B SANOFI SANOFI / FORM 20-F 2019 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 20-F ________________________ (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...